NLS Europe

Dutch life science investor Forbion has raised EUR 2.3 billion (USD 2.6 billion) across two new funds. This is a record for the firm and one of the largest life science venture capital raises globally in the past five years. The new money comes into a European biotech market that has long been short of growth capital.

After an “incredibly difficult time”, the life science industry in the UK is showing clear signs of renewed momentum as venture capital is edging upward and activity across the ecosystem is intensifying.

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).

With an intended investment volume of more than EUR 200 million over the next 5 years, Fresenius Ventures targets growth fields adjacent to Fresenius’ existing strategic platforms (Bio)Pharma, MedTech, and Care Provision. 

Spanish biochemist and molecular biologist Salvador Aznar Benitah’s research focuses on how adult stem cells function in normal conditions, aging, and cancer, with particular interest in epigenetics, circadian rhythms, and the mechanisms that allow certain cancer cells to initiate metastasis.

The new hub marks an investment in software development and clinical expertise and brings together these capabilities to accelerate the path to one intelligent digital ecosystem across the full perioperative workflow.